Harrow (NASDAQ:HROW – Get Free Report) and IM Cannabis (NASDAQ:IMCC – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Valuation and Earnings
This table compares Harrow and IM Cannabis”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Harrow | $275.59 million | 4.02 | -$5.14 million | ($1.00) | -29.58 |
| IM Cannabis | $45.80 million | 0.01 | -$8.10 million | ($60.66) | -0.03 |
Risk and Volatility
Harrow has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500.
Profitability
This table compares Harrow and IM Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Harrow | -13.51% | -38.00% | -3.37% |
| IM Cannabis | -39.62% | N/A | -58.32% |
Analyst Ratings
This is a summary of current ratings and price targets for Harrow and IM Cannabis, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Harrow | 1 | 2 | 7 | 0 | 2.60 |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
Harrow currently has a consensus target price of $66.17, indicating a potential upside of 123.70%. Given Harrow’s stronger consensus rating and higher probable upside, research analysts plainly believe Harrow is more favorable than IM Cannabis.
Institutional & Insider Ownership
72.8% of Harrow shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 5.9% of IM Cannabis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Harrow beats IM Cannabis on 11 of the 14 factors compared between the two stocks.
About Harrow
Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
